An efficient and scalable method for the direct isolation of stable α-form crystals of Mirabegron (1) is developed. The developed method negates transformation of metastable β-form crystals into α-form crystals thereby overcoming the limitations of reported methods and avoids additional processing steps during its manufacture. The developed method directly provides stable α-form crystals of Mirabegron (1) with yield of around 84% and purity of >99.77% by HPLC in a single step.
Introduction
Crystallization operation is often critical in pharmaceutical industries as it solely determines product properties such as the polymorphism, crystal size distribution, and crystal habit. 1 Change in polymorphic form may alter product characteristics such as dissolution, hardness, color, optical properties, melting point or chemical reactivity. As regulatory perspective, developing the process which provides exclusively pure polymorph of a drug substance that should be stable enough to maintain the polymorph integrity during formulation of the drug product and storage throughout its life cycle is very necessary. The driving force in crystal formation is super saturation and when a super saturation of crystallizing compound is created by chemical reaction, the operation is known as reactive crystallization. In reactive crystallization, reactions can be very fast compared to the mass transfer rates and growth rates to the crystals thus reactive crystallizations can lead to the exclusive formation of the metastable polymorph of a system. 2 This article is aimed to provide a case study wherein systematic crystallization of stable α-form crystals of Mirabegron (1) is achieved by circumventing the following limitations of the known processes; (a) reactive crystallization of metastable β-form crystals of 1 and (b) transformation of metastable β-form crystals into α-form crystals using a seed.
Background
Mirabegron (1), chemically known as 2-(2-amino-
acetamide is a selective agonist for the human beta 3-adrenoceptor 3 (β 3 -AR) approved for the symptomatic treatment of urinary urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (OAB) syndrome. [4] [5] Mirabegron has distinct and novel mechanism of action compared to antimuscarinics 6 as it improves the storage capacity of the bladder without inhibiting bladder voiding thereby prolonging the time between trips to the toilet for the patient. 5 Mirabegron (1) According to the literature reports Mirabegron free base exhibits polymorphism and is know to possess two crystalline forms, namely α-form and β-form crystals. The β-form crystals of mirabegron is hygroscopic and tends to gain water content up to 3% under the relative humidity of about 20%, whereas α-form crystals did not show any increase in the water content over the entire range of relative humidity from 5% to 95% concluding that α-crystal form is stable and suitable for use as a medicine. 9 According to EMA assessment report, Betmiga formulation is known to contain α-crystalline form of mirabegron free base. 5 The first generation syntheses 10 discloses two synthetic approaches for 1 (Schemes 1 and 2 ). The first approach (Scheme 1) involves condensation of Boc-protected aniline 2 with thiazole acid 3 to obtain Boc-protected intermediate 1a.
The Boc group was de-protected in 1a using HCl to furnish di-hydrochloride salt of 1 with an overall yield of about 26% over two stages. However, this report does not exemplify the isolation of free base of mirabegron (1) .
The second approach (Scheme 2) mentioned in the report is shuffling of synthetic steps of Scheme 1. In the second approach, benzyl (Bn) protected secondary amine 4 was reacted with (R)-styrene oxide (5) to provide Bnprotected intermediate 1b. However, detailed synthetic procedure is not provided in the report for this approach. Neither of these approaches have provided procedure for preparing mirabegron free base (1) which has been used to formulate drug product and clarity on polymorphic forms associated with free base.
Second generation synthesis 9 (Scheme 3) reported for 1 involves coupling of 6 with 3 followed by addition of aqueous sodium hydroxide solution to provide β-crystal form directly from the reaction mass through reactive crystallization. β-Form crystals was then re-crystallized in subsequent stage in aqueous ethanol using seeds of α-crystals to provide α-crystal form with 74-78% yield over two stages. Though second generation synthesis is improved over first generation but has a limitation to perform additional manufacturing step of converting β-form crystals into α-form crystals using seeds of α-crystals. This additional step to achieve α-form decreases the efficiency in terms of yield loss and productivity. However reported transformation of β-form crystals to α-form crystals lack consistency in providing pure α-form crystals at our end. Several other known methods for the preparation of α-form involves additional crystallization of the isolated material using various solvent systems. 11 Most importantly the desired crystals achieved via polymorphic transformation generally pose increased risk of polymorph contamination (polymorphic purity) during the manufacturing process as well as during its stability studies. Thus, it may be difficult to maintain the integrity of the polymorphs which are achieved via transformation of metastable form / pseudo form. This triggered us to aim for the process which could directly produce α-form crystals selectively and directly through a proper solventmediated crystallization process. The details of process optimization work carried out in providing a single stage met-hod for direct isolation of α-form crystals which is suitable for industrial scale are discussed herein.
Results and Discussion
Our initial approach to achieve α-form crystals obviating the polymorphic transformations was to replace the reported reaction medium (water) with a suitable organic solvent. The purpose of replacing the water with organic solvent before neutralizing the reaction mass was to avoid the reactive crystallization and to retain the product in solution phase. Among the several solvents explored for the reaction, methanol showed moderately good conversion of 6 to 1 in solution state. The reaction mixture was then neutralized with aqueous solution of sodium hydroxide as base and obtained clear solution was concentrated to provide crude residue, which was dissolved in organic solvent, filtered to remove the insoluble inorganic material and crystallization of 1 was explored using various solvents and anti-solvents, but the approach was unsuccessful as it provided impure and hygroscopic solids.
In our next approach, water was retained as a reaction solvent and water immiscible organic solvent was added to the reaction mass prior to basification to extract the product into the organic phase to arrest reactive crystallization of β-form. The organic phase containing the product was then separated and crystallization was attempted using anti-solvent(s) preferentially to achieve pure α-form crystals of 1. Among several solvents explored for extraction, ethyl acetate as a solvent and nheptane, toluene, MIBK, DIPE as anti-solvents exclusively provided pure α-crystalline form. However, this combination of solvent and anti-solvents failed to provide chemical purity as per ICH 12 requirement. Additionally, poor solubility of 1 in ethyl acetate necessitated huge volume of ethyl acetate (around 25 volumes/g of 6) for complete extraction of 1 even at the elevated temperature. The yields obtained with this approach were also not satisfactory. Attempts to achieve yield and ICH quality material by judicious choice of anti-solvents were not successful. The results of the various combinations of solvent(s) and anti-solvent explored in this approach are provided in Table 1 . To overcome the issues associated with ethyl acetate, extraction of 1 was attempted with an amphiphilic solvent that was polar enough to solubilize the molecule but had enough hydrophobicity to have very limited miscibility with water. n-Butanol has all the attributes that we were looking in a solvent to be used for extraction of 1. The exploratory reactions using n-butanol (Table 2 ; entries 1 and 2) furnished 1 with comparable yields and purity to those obtained with ethyl acetate. More importantly, only 10-12 volumes of n-butanol were sufficient to extract as opposed to 25 volumes of ethyl acetate. In addition to this, the extraction of 1 could be carried out at room temperature. This made n-butanol the perfect choice since it hit the štrifecta' for all that was desired in the solvent of choice. Among the two preferred anti solvents (n-heptane and toluene), toluene furnished extremely promising results with n-butanol with respect to chemical purity and yield as shown in Table 2 .
Further, to improve the yield of 1, around half of the volume of n-butanol used for the extraction was concentrated in vacuuo below 70 °C before the toluene was added as anti-solvent. The mixture was gradually cooled to 25-30 °C, precipitated solid was filtered and dried under vacuum at 55-60 °C to get 1 with 84% yield and 99.86% purity by HPLC. Around 10% yield was increased without compromising on stringent quality requirements with this modification. The trend data of yield, purity and polymorphic form for kilogram-scale batches is provided in Table 2 (entries 5 and 6).
The schematic representation of single step process for achieving the α-form crystals is provided in Scheme 4 and structure of impurities controlled during the crystallization process are provided in Figure 1. 
Conclusion
In conclusion, an efficient and robust method for direct isolation of the α-form crystals of mirabegron (1) has been developed using n-butanol mediated work-up. The developed process provided α-form crystals obviating the subsequent recrystallization step necessitated by earlier methods with an overall yield of around 84% and purity of around 99.77% by HPLC.
Experimental Section

1 General
All reagents, solvents, and processing aids are commercial products and were used as received. For reactions run of pilot scale, glass line reactors having variable rate agitation, with -10 to 150 °C jacket temperature range were used for the reaction. 1 H NMR spectra was recorded in DMSO-d 6 using Varian Gemini 400 MHz FT NMR spectrometer; the chemical shifts are reported in δ ppm relative to TMS. ESI mass spectra were performed on the Shimatzu LCMS-2020 spectrometer. Related substance purity was monitored by high performance liquid chromatography (HPLC) on Agilent Technologies 1200 series. The gas chromatography on Agilent Technologies 7683B with head space was used for analyzing the residual solvents.
2. HPLC Method for Calculating the Chemical, Assay and Chiral Purity
Related substances, assay and chiral purity of Mirabegron (1) were estimated by a gradient HPLC analysis method developed at Megafine. (1) is about 16.8 min. (c) Samples generated as described in the solid form were typically analyzed by X-ray powder diffractogram (XRPD). XRPD was conducted on a Bruker D8 advance X-ray powder diffractometer using Cu Kα radiation at 1.54. The instrument was equipped with a fine focus X-ray tube. The voltage and amperage of X-ray generator were set at 40 kV and 80 mA, respectively. The divergence slices were set at 0.3°. The diffracted radiation was detected by a Lynx Eye detector. Typically, a theta-two theta continuous scan at 4.95°/min (0.4 sec/0.033° step) from 2° 2θ to 50° 2θ was used. A corundum probe standard was used to check the peak position. In general, positions of XRPD peaks are expected to individually vary on a measurement-by-measurement basis by about ± 0.2° 2θ.
